AYTU Stock Analysis: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$2.25
0.00 (0.00%)
▲
5d:
+2.27%
30d:
+5.63%
90d:
-14.45%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AYTU shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: AYTU shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $2.25, which is considered slightly high relative to its 30-day fair value range of $2.11 to $2.26. From a valuation perspective, the stock is trading at a discount (Forward PE: -30.0) compared to its historical average (14.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is in a downtrend. Immediate support is located at $2.08, while resistance sits at $2.35.
Market Sentiment: AYTU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+322.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AYTU is in a downtrend. Immediate support is located at $2.08, while resistance sits at $2.35.
Market Sentiment: AYTU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+322.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.11 -
$2.26
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.0%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 322.2% below Wall St target ($9.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.11 -
$2.26
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.08
Resistance Level
$2.35
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-30.00
Wall Street Target
$9.50
(+322.2%)
Revenue Growth (YoY)
-32.7%
Profit Margin
-60.2%
PE vs Historical
-30.0 vs 14.8
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 3:56 PM ET
Data refreshes hourly during market hours. Next update: 4:56 PM
Data refreshes hourly during market hours. Next update: 4:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
